| 7-Nitroindazole | The risk or severity of adverse effects can be increased when Ropivacaine is combined with 7-Nitroindazole. | Experimental |
| Abiraterone | The serum concentration of Ropivacaine can be increased when it is combined with Abiraterone. | Approved |
| Acebutolol | The risk or severity of adverse effects can be increased when Acebutolol is combined with Ropivacaine. | Approved |
| Acepromazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Acepromazine. | Approved, Vet Approved |
| Aceprometazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Aceprometazine. | Approved |
| Acetazolamide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Acetazolamide. | Approved, Vet Approved |
| Adipiplon | The risk or severity of adverse effects can be increased when Ropivacaine is combined with adipiplon. | Investigational |
| Agomelatine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Agomelatine. | Approved, Investigational |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropivacaine. | Approved |
| Alfaxalone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Alfaxalone. | Vet Approved |
| Alfentanil | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Alfentanil. | Approved, Illicit |
| Aliskiren | The risk or severity of adverse effects can be increased when Aliskiren is combined with Ropivacaine. | Approved, Investigational |
| Allopregnanolone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sage 547. | Investigational |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Alphacetylmethadol. | Experimental, Illicit |
| Alprazolam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Alprazolam. | Approved, Illicit, Investigational |
| Amifostine | The risk or severity of adverse effects can be increased when Amifostine is combined with Ropivacaine. | Approved, Investigational |
| Amiloride | The risk or severity of adverse effects can be increased when Amiloride is combined with Ropivacaine. | Approved |
| Amiodarone | The metabolism of Ropivacaine can be decreased when combined with Amiodarone. | Approved, Investigational |
| Amisulpride | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amisulpride. | Approved, Investigational |
| Amitriptyline | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amitriptyline. | Approved |
| Amlodipine | The risk or severity of adverse effects can be increased when Amlodipine is combined with Ropivacaine. | Approved |
| Amobarbital | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amobarbital. | Approved, Illicit |
| Amoxapine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amoxapine. | Approved |
| Amperozide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amperozide. | Experimental |
| Amphotericin B | The risk or severity of adverse effects can be increased when Amphotericin B is combined with Ropivacaine. | Approved, Investigational |
| Amyl Nitrite | The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Ropivacaine. | Approved |
| Apomorphine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Ropivacaine. | Approved, Investigational |
| Apraclonidine | The risk or severity of adverse effects can be increased when Apraclonidine is combined with Ropivacaine. | Approved |
| Aprepitant | The serum concentration of Ropivacaine can be increased when it is combined with Aprepitant. | Approved, Investigational |
| Aripiprazole | Aripiprazole may increase the hypotensive activities of Ropivacaine. | Approved, Investigational |
| Arotinolol | The risk or severity of adverse effects can be increased when Arotinolol is combined with Ropivacaine. | Approved |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropivacaine. | Approved, Investigational |
| Artemether | The metabolism of Ropivacaine can be decreased when combined with Artemether. | Approved |
| Articaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Articaine. | Approved |
| Asenapine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Asenapine. | Approved |
| Atazanavir | The metabolism of Ropivacaine can be decreased when combined with Atazanavir. | Approved, Investigational |
| Atenolol | The risk or severity of adverse effects can be increased when Atenolol is combined with Ropivacaine. | Approved |
| Atomoxetine | The metabolism of Ropivacaine can be decreased when combined with Atomoxetine. | Approved |
| Azelastine | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. | Approved |
| Azelastine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Azelastine. | Approved |
| Azilsartan medoxomil | The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ropivacaine. | Approved |
| Azithromycin | The metabolism of Ropivacaine can be decreased when combined with Azithromycin. | Approved |
| Baclofen | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Baclofen. | Approved |
| Barbexaclone | Barbexaclone may increase the hypotensive activities of Ropivacaine. | Experimental |
| Barbital | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Barbital. | Illicit |
| Barnidipine | The risk or severity of adverse effects can be increased when Barnidipine is combined with Ropivacaine. | Approved |
| Benazepril | The risk or severity of adverse effects can be increased when Benazepril is combined with Ropivacaine. | Approved, Investigational |
| Bendroflumethiazide | The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Ropivacaine. | Approved |
| Benperidol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Benperidol. | Investigational |
| Benzocaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Benzocaine. | Approved |
| Benzyl alcohol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Benzyl alcohol. | Approved |
| Bepridil | The risk or severity of adverse effects can be increased when Bepridil is combined with Ropivacaine. | Approved, Withdrawn |
| Betaxolol | The metabolism of Ropivacaine can be decreased when combined with Betaxolol. | Approved |
| Bexarotene | The serum concentration of Ropivacaine can be decreased when it is combined with Bexarotene. | Approved, Investigational |
| Bisoprolol | The risk or severity of adverse effects can be increased when Bisoprolol is combined with Ropivacaine. | Approved |
| Boceprevir | The metabolism of Ropivacaine can be decreased when combined with Boceprevir. | Approved, Investigational |
| Bortezomib | The metabolism of Ropivacaine can be decreased when combined with Bortezomib. | Approved, Investigational |
| Bosentan | The serum concentration of Ropivacaine can be decreased when it is combined with Bosentan. | Approved, Investigational |
| Bretylium | The risk or severity of adverse effects can be increased when Bretylium is combined with Ropivacaine. | Approved |
| Brexpiprazole | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Brexpiprazole. | Approved |
| Brimonidine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Brimonidine. | Approved |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved |
| Bromazepam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Bromazepam. | Approved, Illicit |
| Bromocriptine | The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ropivacaine. | Approved, Investigational |
| Brompheniramine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Brompheniramine. | Approved |
| Brotizolam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Brotizolam. | Approved, Withdrawn |
| Bumetanide | The risk or severity of adverse effects can be increased when Bumetanide is combined with Ropivacaine. | Approved |
| Bupivacaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Bupivacaine. | Approved, Investigational |
| Buprenorphine | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. | Approved, Illicit, Investigational, Vet Approved |
| Bupropion | The metabolism of Ropivacaine can be decreased when combined with Bupropion. | Approved |
| Buspirone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Buspirone. | Approved, Investigational |
| Butabarbital | The risk or severity of adverse effects can be increased when Butabarbital is combined with Ropivacaine. | Approved, Illicit |
| Butalbital | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Butalbital. | Approved, Illicit |
| Butethal | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Butethal. | Approved, Illicit |
| Butorphanol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Butorphanol. | Approved, Illicit, Vet Approved |
| Caffeine | The metabolism of Ropivacaine can be decreased when combined with Caffeine. | Approved |
| Canagliflozin | The risk or severity of adverse effects can be increased when Canagliflozin is combined with Ropivacaine. | Approved |
| Candesartan | The risk or severity of adverse effects can be increased when Candesartan is combined with Ropivacaine. | Approved |
| Captopril | The risk or severity of adverse effects can be increased when Captopril is combined with Ropivacaine. | Approved |
| Carbamazepine | The metabolism of Ropivacaine can be increased when combined with Carbamazepine. | Approved, Investigational |
| Carbetocin | The risk or severity of adverse effects can be increased when Carbetocin is combined with Ropivacaine. | Approved |
| Carbinoxamine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Carbinoxamine. | Approved |
| Carfentanil | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Carfentanil. | Illicit, Vet Approved |
| Carisoprodol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Carisoprodol. | Approved |
| Carteolol | The risk or severity of adverse effects can be increased when Carteolol is combined with Ropivacaine. | Approved |
| Carvedilol | The risk or severity of adverse effects can be increased when Carvedilol is combined with Ropivacaine. | Approved, Investigational |
| Celecoxib | The metabolism of Ropivacaine can be decreased when combined with Celecoxib. | Approved, Investigational |
| Ceritinib | The serum concentration of Ropivacaine can be increased when it is combined with Ceritinib. | Approved |
| Cetirizine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Cetirizine. | Approved |
| Chloral hydrate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloral hydrate. | Approved, Illicit, Vet Approved |
| Chlordiazepoxide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlordiazepoxide. | Approved, Illicit |
| Chlormezanone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlormezanone. | Approved, Withdrawn |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloroprocaine. | Approved |
| Chloroquine | The metabolism of Ropivacaine can be decreased when combined with Chloroquine. | Approved, Vet Approved |
| Chlorothiazide | The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ropivacaine. | Approved, Vet Approved |
| Chlorphenamine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorphenamine. | Approved |
| Chlorpromazine | The metabolism of Ropivacaine can be decreased when combined with Chlorpromazine. | Approved, Vet Approved |
| Chlorprothixene | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorprothixene. | Approved, Withdrawn |
| Chlorthalidone | The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Ropivacaine. | Approved |
| Chlorzoxazone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorzoxazone. | Approved |
| Cholecalciferol | The metabolism of Ropivacaine can be decreased when combined with Cholecalciferol. | Approved, Nutraceutical |
| Cilazapril | The risk or severity of adverse effects can be increased when Cilazapril is combined with Ropivacaine. | Approved |
| Cilnidipine | The risk or severity of adverse effects can be increased when Cilnidipine is combined with Ropivacaine. | Approved |
| Cimetidine | The metabolism of Ropivacaine can be decreased when combined with Cimetidine. | Approved |
| Cinacalcet | The metabolism of Ropivacaine can be decreased when combined with Cinacalcet. | Approved |
| Cinchocaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Cinchocaine. | Approved, Vet Approved |
| Ciprofloxacin | The serum concentration of Ropivacaine can be increased when it is combined with Ciprofloxacin. | Approved, Investigational |
| Citalopram | The metabolism of Ropivacaine can be decreased when combined with Citalopram. | Approved |
| Clarithromycin | The metabolism of Ropivacaine can be decreased when combined with Clarithromycin. | Approved |
| Clemastine | The metabolism of Ropivacaine can be decreased when combined with Clemastine. | Approved |
| Clevidipine | The risk or severity of adverse effects can be increased when Clevidipine is combined with Ropivacaine. | Approved |
| Clidinium | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Clidinium. | Approved |
| Clobazam | The metabolism of Ropivacaine can be decreased when combined with Clobazam. | Approved, Illicit |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ropivacaine. | Approved, Investigational |
| Clomipramine | The metabolism of Ropivacaine can be decreased when combined with Clomipramine. | Approved, Vet Approved |
| Clonazepam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonazepam. | Approved, Illicit |
| Clonidine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonidine. | Approved |
| Clopidogrel | The metabolism of Ropivacaine can be decreased when combined with Clopidogrel. | Approved, Nutraceutical |
| Clorazepate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Clorazepate. | Approved, Illicit |
| Clotrimazole | The metabolism of Ropivacaine can be decreased when combined with Clotrimazole. | Approved, Vet Approved |
| Clozapine | The metabolism of Ropivacaine can be decreased when combined with Clozapine. | Approved |
| Cobicistat | The serum concentration of Ropivacaine can be increased when it is combined with Cobicistat. | Approved |
| Cocaine | The metabolism of Ropivacaine can be decreased when combined with Cocaine. | Approved, Illicit |
| Codeine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Codeine. | Approved, Illicit |
| Conivaptan | The serum concentration of Ropivacaine can be increased when it is combined with Conivaptan. | Approved, Investigational |
| Crizotinib | The metabolism of Ropivacaine can be decreased when combined with Crizotinib. | Approved |
| Cyclizine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclizine. | Approved |
| Cyclobenzaprine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclobenzaprine. | Approved |
| Cyclosporine | The metabolism of Ropivacaine can be decreased when combined with Cyclosporine. | Approved, Investigational, Vet Approved |
| Cyproheptadine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyproheptadine. | Approved |
| Cyproterone acetate | The serum concentration of Ropivacaine can be decreased when it is combined with Cyproterone acetate. | Approved, Investigational |
| Dabrafenib | The serum concentration of Ropivacaine can be decreased when it is combined with Dabrafenib. | Approved |
| Dantrolene | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dantrolene. | Approved |
| Dapagliflozin | The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Ropivacaine. | Approved |
| Dapiprazole | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapiprazole. | Approved |
| Dapoxetine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapoxetine. | Investigational |
| Darifenacin | The metabolism of Ropivacaine can be decreased when combined with Darifenacin. | Approved, Investigational |
| Darunavir | The serum concentration of Ropivacaine can be increased when it is combined with Darunavir. | Approved |
| Dasatinib | The serum concentration of Ropivacaine can be increased when it is combined with Dasatinib. | Approved, Investigational |
| Deferasirox | The serum concentration of Ropivacaine can be decreased when it is combined with Deferasirox. | Approved, Investigational |
| Delavirdine | The metabolism of Ropivacaine can be decreased when combined with Delavirdine. | Approved |
| Deramciclane | The risk or severity of adverse effects can be increased when Ropivacaine is combined with deramciclane. | Investigational |
| Desflurane | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Desflurane. | Approved |
| Desipramine | The metabolism of Ropivacaine can be decreased when combined with Desipramine. | Approved |
| Desloratadine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Desloratadine. | Approved, Investigational |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Desvenlafaxine. | Approved |
| Dexamethasone | The serum concentration of Ropivacaine can be decreased when it is combined with Dexamethasone. | Approved, Investigational, Vet Approved |
| Dexbrompheniramine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexbrompheniramine. | Approved |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexmedetomidine. | Approved, Vet Approved |
| Dextromoramide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextromoramide. | Experimental, Illicit |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextropropoxyphene. | Approved, Illicit, Withdrawn |
| Dezocine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dezocine. | Approved |
| Diazepam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Diazepam. | Approved, Illicit, Vet Approved |
| Diclofenamide | The risk or severity of adverse effects can be increased when Diclofenamide is combined with Ropivacaine. | Approved |
| Difenoxin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Difenoxin. | Approved, Illicit |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydrocodeine. | Approved, Illicit |
| Dihydroergotamine | The metabolism of Ropivacaine can be decreased when combined with Dihydroergotamine. | Approved |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydroetorphine. | Experimental, Illicit |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydromorphine. | Experimental, Illicit |
| Diltiazem | The metabolism of Ropivacaine can be decreased when combined with Diltiazem. | Approved |
| Dimenhydrinate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dimenhydrinate. | Approved |
| Dinutuximab | The risk or severity of adverse effects can be increased when Dinutuximab is combined with Ropivacaine. | Approved |
| Diphenhydramine | The metabolism of Ropivacaine can be decreased when combined with Diphenhydramine. | Approved |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Diphenoxylate. | Approved, Illicit |
| Dipyridamole | The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ropivacaine. | Approved |
| Doxazosin | The risk or severity of adverse effects can be increased when Doxazosin is combined with Ropivacaine. | Approved |
| Doxepin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Doxepin. | Approved |
| Doxorubicin | The metabolism of Ropivacaine can be decreased when combined with Doxorubicin. | Approved, Investigational |
| Doxycycline | The metabolism of Ropivacaine can be decreased when combined with Doxycycline. | Approved, Investigational, Vet Approved |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved, Vet Approved |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved, Illicit |
| Dronedarone | The metabolism of Ropivacaine can be decreased when combined with Dronedarone. | Approved |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved, Vet Approved |
| Drotebanol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Drotebanol. | Experimental, Illicit |
| Duloxetine | Ropivacaine may increase the orthostatic hypotensive activities of Duloxetine. | Approved |
| Dyclonine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine. | Approved |
| Ecgonine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ecgonine. | Experimental, Illicit |
| Ecopipam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ecopipam. | Investigational |
| Efavirenz | The serum concentration of Ropivacaine can be decreased when it is combined with Efavirenz. | Approved, Investigational |
| Efonidipine | The risk or severity of adverse effects can be increased when Efonidipine is combined with Ropivacaine. | Approved |
| Eliglustat | The metabolism of Ropivacaine can be decreased when combined with Eliglustat. | Approved |
| Eltanolone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pregnanolone. | Investigational |
| Empagliflozin | The risk or severity of adverse effects can be increased when Empagliflozin is combined with Ropivacaine. | Approved |
| Enalapril | The risk or severity of adverse effects can be increased when Enalapril is combined with Ropivacaine. | Approved, Vet Approved |
| Enalaprilat | The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropivacaine. | Approved |
| Enflurane | The risk or severity of adverse effects can be increased when Enflurane is combined with Ropivacaine. | Approved, Vet Approved |
| Entacapone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Entacapone. | Approved, Investigational |
| Enzalutamide | The serum concentration of Ropivacaine can be decreased when it is combined with Enzalutamide. | Approved |
| Eplerenone | The risk or severity of adverse effects can be increased when Eplerenone is combined with Ropivacaine. | Approved |
| Epoprostenol | The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ropivacaine. | Approved |
| Eprosartan | The risk or severity of adverse effects can be increased when Eprosartan is combined with Ropivacaine. | Approved |
| Erythromycin | The metabolism of Ropivacaine can be decreased when combined with Erythromycin. | Approved, Vet Approved |
| Escitalopram | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Escitalopram. | Approved, Investigational |
| Eslicarbazepine acetate | The serum concentration of Ropivacaine can be decreased when it is combined with Eslicarbazepine acetate. | Approved |
| Esmolol | The risk or severity of adverse effects can be increased when Esmolol is combined with Ropivacaine. | Approved |
| Estazolam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Estazolam. | Approved, Illicit |
| Eszopiclone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Eszopiclone. | Approved |
| Etacrynic acid | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ropivacaine. | Approved |
| Ethanol | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. | Approved |
| Ethchlorvynol | The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ropivacaine. | Approved, Illicit, Withdrawn |
| Ethosuximide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethosuximide. | Approved |
| Ethotoin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethotoin. | Approved |
| Ethyl carbamate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl carbamate. | Withdrawn |
| Ethyl loflazepate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl loflazepate. | Approved, Illicit |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethylmorphine. | Approved, Illicit |
| Etidocaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etidocaine. | Approved |
| Etifoxine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etifoxine. | Withdrawn |
| Etizolam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etizolam. | Approved |
| Etomidate | The risk or severity of adverse effects can be increased when Etomidate is combined with Ropivacaine. | Approved |
| Etoperidone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etoperidone. | Approved |
| Etorphine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etorphine. | Illicit, Vet Approved |
| Etravirine | The serum concentration of Ropivacaine can be decreased when it is combined with Etravirine. | Approved |
| Ezogabine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ezogabine. | Approved |
| Felbamate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Felbamate. | Approved |
| Felodipine | The risk or severity of adverse effects can be increased when Felodipine is combined with Ropivacaine. | Approved, Investigational |
| Fencamfamine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fencamfamine. | Approved, Illicit, Withdrawn |
| Fenoldopam | The risk or severity of adverse effects can be increased when Fenoldopam is combined with Ropivacaine. | Approved |
| Fentanyl | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fentanyl. | Approved, Illicit, Investigational, Vet Approved |
| Fexofenadine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fexofenadine. | Approved |
| Fimasartan | The risk or severity of adverse effects can be increased when Fimasartan is combined with Ropivacaine. | Approved |
| Flibanserin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Flibanserin. | Approved |
| Fluconazole | The metabolism of Ropivacaine can be decreased when combined with Fluconazole. | Approved |
| Fludiazepam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fludiazepam. | Approved, Illicit |
| Flunarizine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Flunarizine. | Approved |
| Flunitrazepam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Flunitrazepam. | Approved, Illicit |
| Fluoxetine | The metabolism of Ropivacaine can be decreased when combined with Fluoxetine. | Approved, Vet Approved |
| Flupentixol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Flupentixol. | Approved, Withdrawn |
| Fluphenazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluphenazine. | Approved |
| Flurazepam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Flurazepam. | Approved, Illicit |
| Fluspirilene | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluspirilene. | Approved |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluticasone Propionate. | Approved |
| Fluvoxamine | The serum concentration of Ropivacaine can be increased when it is combined with Fluvoxamine. | Approved, Investigational |
| Fosamprenavir | The metabolism of Ropivacaine can be decreased when combined with Fosamprenavir. | Approved |
| Fosaprepitant | The serum concentration of Ropivacaine can be increased when it is combined with Fosaprepitant. | Approved |
| Fosinopril | The risk or severity of adverse effects can be increased when Fosinopril is combined with Ropivacaine. | Approved |
| Fosphenytoin | The metabolism of Ropivacaine can be increased when combined with Fosphenytoin. | Approved |
| Fospropofol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fospropofol. | Approved, Illicit |
| Furosemide | The risk or severity of adverse effects can be increased when Furosemide is combined with Ropivacaine. | Approved, Vet Approved |
| Fusidic Acid | The serum concentration of Ropivacaine can be increased when it is combined with Fusidic Acid. | Approved |
| Gabapentin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Gabapentin. | Approved, Investigational |
| Gabapentin Enacarbil | The risk or severity of adverse effects can be increased when Ropivacaine is combined with gabapentin enacarbil. | Approved |
| Gamma Hydroxybutyric Acid | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Gamma Hydroxybutyric Acid. | Approved, Illicit |
| Gepirone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Gepirone. | Investigational |
| Glutethimide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Glutethimide. | Approved, Illicit |
| Guanfacine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Guanfacine. | Approved, Investigational |
| Halazepam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Halazepam. | Approved, Illicit, Withdrawn |
| Haloperidol | The metabolism of Ropivacaine can be decreased when combined with Haloperidol. | Approved |
| Halothane | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Halothane. | Approved, Vet Approved |
| Heroin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Heroin. | Approved, Illicit |
| Hexobarbital | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Hexobarbital. | Approved |
| Hyaluronidase | The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ropivacaine. | Approved, Investigational |
| Hydralazine | The risk or severity of adverse effects can be increased when Hydralazine is combined with Ropivacaine. | Approved |
| Hydrochlorothiazide | The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Ropivacaine. | Approved, Vet Approved |
| Hydrocodone | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. | Approved, Illicit |
| Hydroflumethiazide | The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ropivacaine. | Approved |
| Hydromorphone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydromorphone. | Approved, Illicit |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved |
| Idelalisib | The serum concentration of Ropivacaine can be increased when it is combined with Idelalisib. | Approved |
| Iloperidone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Iloperidone. | Approved |
| Iloprost | The risk or severity of adverse effects can be increased when Iloprost is combined with Ropivacaine. | Approved, Investigational |
| Imatinib | The metabolism of Ropivacaine can be decreased when combined with Imatinib. | Approved |
| Imidapril | The risk or severity of adverse effects can be increased when Imidapril is combined with Ropivacaine. | Investigational |
| Imipramine | The metabolism of Ropivacaine can be decreased when combined with Imipramine. | Approved |
| Indalpine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Indalpine. | Investigational, Withdrawn |
| Indapamide | The risk or severity of adverse effects can be increased when Indapamide is combined with Ropivacaine. | Approved |
| Indinavir | The metabolism of Ropivacaine can be decreased when combined with Indinavir. | Approved |
| Indoramin | The risk or severity of adverse effects can be increased when Indoramin is combined with Ropivacaine. | Withdrawn |
| Irbesartan | The risk or severity of adverse effects can be increased when Irbesartan is combined with Ropivacaine. | Approved, Investigational |
| Isavuconazonium | The metabolism of Ropivacaine can be decreased when combined with Isavuconazonium. | Approved, Investigational |
| Isocarboxazid | The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ropivacaine. | Approved |
| Isoflurane | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Isoflurane. | Approved, Vet Approved |
| Isoniazid | The metabolism of Ropivacaine can be decreased when combined with Isoniazid. | Approved |
| Isosorbide Dinitrate | The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Ropivacaine. | Approved |
| Isosorbide Mononitrate | The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Ropivacaine. | Approved |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Ropivacaine. | Approved, Withdrawn |
| Isradipine | The metabolism of Ropivacaine can be decreased when combined with Isradipine. | Approved |
| Itraconazole | The metabolism of Ropivacaine can be decreased when combined with Itraconazole. | Approved, Investigational |
| Ivacaftor | The serum concentration of Ropivacaine can be increased when it is combined with Ivacaftor. | Approved |
| Ketamine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketamine. | Approved, Vet Approved |
| Ketazolam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketazolam. | Approved |
| Ketobemidone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketobemidone. | Approved |
| Ketoconazole | The metabolism of Ropivacaine can be decreased when combined with Ketoconazole. | Approved, Investigational |
| Labetalol | The risk or severity of adverse effects can be increased when Labetalol is combined with Ropivacaine. | Approved |
| Lacidipine | The risk or severity of adverse effects can be increased when Lacidipine is combined with Ropivacaine. | Approved |
| Lamotrigine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lamotrigine. | Approved, Investigational |
| Lercanidipine | The risk or severity of adverse effects can be increased when Lercanidipine is combined with Ropivacaine. | Approved, Investigational |
| Levetiracetam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levetiracetam. | Approved, Investigational |
| Levobunolol | The risk or severity of adverse effects can be increased when Levobunolol is combined with Ropivacaine. | Approved |
| Levobupivacaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levobupivacaine. | Approved |
| Levocabastine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levocabastine. | Approved |
| Levocetirizine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levocetirizine. | Approved |
| Levodopa | Ropivacaine may increase the orthostatic hypotensive activities of Levodopa. | Approved |
| Levomethadyl Acetate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomethadyl Acetate. | Approved |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomilnacipran. | Approved |
| Levorphanol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levorphanol. | Approved |
| Levosimendan | The risk or severity of adverse effects can be increased when Levosimendan is combined with Ropivacaine. | Approved, Investigational |
| Lidocaine | The metabolism of Ropivacaine can be decreased when combined with Lidocaine. | Approved, Vet Approved |
| Lisinopril | The risk or severity of adverse effects can be increased when Lisinopril is combined with Ropivacaine. | Approved, Investigational |
| Lithium | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lithium. | Approved |
| Lofentanil | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lofentanil. | Illicit |
| Lofexidine | The risk or severity of adverse effects can be increased when Lofexidine is combined with Ropivacaine. | Approved, Investigational |
| Lopinavir | The metabolism of Ropivacaine can be decreased when combined with Lopinavir. | Approved |
| Loratadine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Loratadine. | Approved |
| Lorazepam | The risk or severity of adverse effects can be increased when Lorazepam is combined with Ropivacaine. | Approved |
| Lorcaserin | The metabolism of Ropivacaine can be decreased when combined with Lorcaserin. | Approved |
| Losartan | The risk or severity of adverse effects can be increased when Losartan is combined with Ropivacaine. | Approved |
| Lovastatin | The metabolism of Ropivacaine can be decreased when combined with Lovastatin. | Approved, Investigational |
| Loxapine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Loxapine. | Approved |
| Luliconazole | The serum concentration of Ropivacaine can be increased when it is combined with Luliconazole. | Approved |
| Lumacaftor | The serum concentration of Ropivacaine can be decreased when it is combined with Lumacaftor. | Approved |
| Lumefantrine | The metabolism of Ropivacaine can be decreased when combined with Lumefantrine. | Approved |
| Lurasidone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lurasidone. | Approved |
| Magnesium Sulfate | Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved, Vet Approved |
| Mannitol | The risk or severity of adverse effects can be increased when Mannitol is combined with Ropivacaine. | Approved, Investigational |
| Maprotiline | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Maprotiline. | Approved |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Ropivacaine. | Approved |
| Meclizine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Meclizine. | Approved |
| Melatonin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Melatonin. | Approved, Nutraceutical, Vet Approved |
| Melperone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Melperone. | Approved |
| Mepivacaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Mepivacaine. | Approved, Vet Approved |
| Meprobamate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Meprobamate. | Approved, Illicit |
| Mesoridazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Mesoridazine. | Approved |
| Metaxalone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Metaxalone. | Approved |
| Methadone | The metabolism of Ropivacaine can be decreased when combined with Methadone. | Approved |
| Methadyl Acetate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methadyl Acetate. | Approved, Illicit |
| Methapyrilene | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methapyrilene. | Withdrawn |
| Methaqualone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methaqualone. | Illicit, Withdrawn |
| Methazolamide | The risk or severity of adverse effects can be increased when Methazolamide is combined with Ropivacaine. | Approved |
| Methocarbamol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methocarbamol. | Approved, Vet Approved |
| Methohexital | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methohexital. | Approved |
| Methotrimeprazine | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. | Approved |
| Methoxyflurane | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methoxyflurane. | Approved, Vet Approved |
| Methsuximide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methsuximide. | Approved |
| Methyclothiazide | The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ropivacaine. | Approved |
| Methyldopa | The risk or severity of adverse effects can be increased when Methyldopa is combined with Ropivacaine. | Approved |
| Methylecgonine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with ECGONINE METHYL ESTER. | Experimental |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methylphenobarbital. | Approved |
| Metipranolol | The risk or severity of adverse effects can be increased when Metipranolol is combined with Ropivacaine. | Approved |
| Metolazone | The risk or severity of adverse effects can be increased when Metolazone is combined with Ropivacaine. | Approved |
| Metoprolol | The metabolism of Ropivacaine can be decreased when combined with Metoprolol. | Approved, Investigational |
| Metyrosine | Ropivacaine may increase the sedative activities of Metyrosine. | Approved |
| Mexiletine | The metabolism of Ropivacaine can be decreased when combined with Mexiletine. | Approved |
| Midazolam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Midazolam. | Approved, Illicit |
| Mifepristone | The serum concentration of Ropivacaine can be increased when it is combined with Mifepristone. | Approved, Investigational |
| Milnacipran | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Milnacipran. | Approved |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved, Investigational |
| Minoxidil | The risk or severity of adverse effects can be increased when Minoxidil is combined with Ropivacaine. | Approved |
| Mirabegron | The metabolism of Ropivacaine can be decreased when combined with Mirabegron. | Approved |
| Mirtazapine | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. | Approved |
| Mitotane | The serum concentration of Ropivacaine can be decreased when it is combined with Mitotane. | Approved |
| Modafinil | The serum concentration of Ropivacaine can be decreased when it is combined with Modafinil. | Approved, Investigational |
| Moexipril | The risk or severity of adverse effects can be increased when Moexipril is combined with Ropivacaine. | Approved |
| Molindone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Molindone. | Approved |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Ropivacaine. | Approved, Investigational |
| Moxonidine | The risk or severity of adverse effects can be increased when Moxonidine is combined with Ropivacaine. | Approved |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved, Investigational |
| Nadolol | The risk or severity of adverse effects can be increased when Nadolol is combined with Ropivacaine. | Approved |
| Nafcillin | The serum concentration of Ropivacaine can be decreased when it is combined with Nafcillin. | Approved |
| Nalbuphine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Nalbuphine. | Approved |
| Nebivolol | The risk or severity of adverse effects can be increased when Nebivolol is combined with Ropivacaine. | Approved, Investigational |
| Nefazodone | The metabolism of Ropivacaine can be decreased when combined with Nefazodone. | Approved, Withdrawn |
| Nelfinavir | The metabolism of Ropivacaine can be decreased when combined with Nelfinavir. | Approved |
| Nesiritide | The risk or severity of adverse effects can be increased when Nesiritide is combined with Ropivacaine. | Approved, Investigational |
| Netupitant | The serum concentration of Ropivacaine can be increased when it is combined with Netupitant. | Approved |
| Nevirapine | The metabolism of Ropivacaine can be increased when combined with Nevirapine. | Approved |
| Nicardipine | The metabolism of Ropivacaine can be decreased when combined with Nicardipine. | Approved |
| Nicorandil | Nicorandil may increase the hypotensive activities of Ropivacaine. | Approved |
| Nifedipine | The risk or severity of adverse effects can be increased when Nifedipine is combined with Ropivacaine. | Approved |
| Nilotinib | The metabolism of Ropivacaine can be decreased when combined with Nilotinib. | Approved, Investigational |
| Nilvadipine | The risk or severity of adverse effects can be increased when Nilvadipine is combined with Ropivacaine. | Approved |
| Nimodipine | The risk or severity of adverse effects can be increased when Nimodipine is combined with Ropivacaine. | Approved |
| Nisoldipine | The risk or severity of adverse effects can be increased when Nisoldipine is combined with Ropivacaine. | Approved |
| Nitrazepam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Nitrazepam. | Approved |
| Nitrendipine | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine. | Approved |
| Nitric Oxide | The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Ropivacaine. | Approved |
| Nitroglycerin | The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Ropivacaine. | Approved, Investigational |
| Nitroprusside | The risk or severity of adverse effects can be increased when Nitroprusside is combined with Ropivacaine. | Approved |
| Nitrous oxide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Nitrous oxide. | Approved, Vet Approved |
| Norflurane | The risk or severity of adverse effects can be increased when Ropivacaine is combined with 1,1,1,2 Tetrafluoroethane. | Investigational |
| Normethadone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Normethadone. | Approved, Illicit |
| Nortriptyline | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Nortriptyline. | Approved |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ropivacaine. | Approved |
| Olanzapine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Olanzapine. | Approved, Investigational |
| Olaparib | The metabolism of Ropivacaine can be decreased when combined with Olaparib. | Approved |
| Olmesartan | The risk or severity of adverse effects can be increased when Olmesartan is combined with Ropivacaine. | Approved, Investigational |
| Olopatadine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Olopatadine. | Approved |
| Ondansetron | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ondansetron. | Approved |
| Opium | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Opium. | Approved, Illicit |
| Orphenadrine | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. | Approved |
| Osanetant | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Osanetant. | Investigational |
| Osimertinib | The serum concentration of Ropivacaine can be increased when it is combined with Osimertinib. | Approved |
| Oxazepam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxazepam. | Approved |
| Oxethazaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxetacaine. | Investigational |
| Oxprenolol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxprenolol. | Approved |
| Oxybuprocaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxybuprocaine. | Approved |
| Oxycodone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxycodone. | Approved, Illicit, Investigational |
| Oxymorphone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxymorphone. | Approved, Investigational, Vet Approved |
| Paclitaxel | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ropivacaine. | Approved, Vet Approved |
| Palbociclib | The serum concentration of Ropivacaine can be increased when it is combined with Palbociclib. | Approved |
| Paliperidone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Paliperidone. | Approved |
| Panobinostat | The serum concentration of Ropivacaine can be increased when it is combined with Panobinostat. | Approved, Investigational |
| Papaverine | The risk or severity of adverse effects can be increased when Papaverine is combined with Ropivacaine. | Approved |
| Paraldehyde | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. | Approved |
| Paroxetine | The metabolism of Ropivacaine can be decreased when combined with Paroxetine. | Approved, Investigational |
| Peginterferon alfa-2b | The serum concentration of Ropivacaine can be decreased when it is combined with Peginterferon alfa-2b. | Approved |
| Penbutolol | The risk or severity of adverse effects can be increased when Penbutolol is combined with Ropivacaine. | Approved, Investigational |
| Pentazocine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pentazocine. | Approved, Vet Approved |
| Pentobarbital | The metabolism of Ropivacaine can be increased when combined with Pentobarbital. | Approved, Vet Approved |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved |
| Perazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Perazine. | Investigational |
| Perindopril | The risk or severity of adverse effects can be increased when Perindopril is combined with Ropivacaine. | Approved |
| Perospirone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Perospirone. | Approved |
| Perphenazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Perphenazine. | Approved |
| Pethidine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pethidine. | Approved |
| Phenelzine | The risk or severity of adverse effects can be increased when Phenelzine is combined with Ropivacaine. | Approved |
| Phenobarbital | The metabolism of Ropivacaine can be increased when combined with Phenobarbital. | Approved |
| Phenoxybenzamine | The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Ropivacaine. | Approved |
| Phentolamine | The risk or severity of adverse effects can be increased when Phentolamine is combined with Ropivacaine. | Approved |
| Phenytoin | The metabolism of Ropivacaine can be increased when combined with Phenytoin. | Approved, Vet Approved |
| Pimozide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pimozide. | Approved |
| Pindolol | The risk or severity of adverse effects can be increased when Pindolol is combined with Ropivacaine. | Approved |
| Pipamperone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipamperone. | Approved |
| Pipotiazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipotiazine. | Approved |
| Piritramide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Piritramide. | Investigational |
| Pomalidomide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pomalidomide. | Approved |
| Posaconazole | The metabolism of Ropivacaine can be decreased when combined with Posaconazole. | Approved, Investigational, Vet Approved |
| Pramipexole | Ropivacaine may increase the sedative activities of Pramipexole. | Approved, Investigational |
| Pramocaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pramocaine. | Approved |
| Prazepam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Prazepam. | Approved, Illicit |
| Prazosin | The risk or severity of adverse effects can be increased when Prazosin is combined with Ropivacaine. | Approved |
| Pregabalin | The risk or severity of adverse effects can be increased when Pregabalin is combined with Ropivacaine. | Approved, Illicit, Investigational |
| Prilocaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Prilocaine. | Approved |
| Primidone | The metabolism of Ropivacaine can be increased when combined with Primidone. | Approved, Vet Approved |
| Procaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Procaine. | Approved, Investigational, Vet Approved |
| Prochlorperazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Prochlorperazine. | Approved, Vet Approved |
| Promazine | The metabolism of Ropivacaine can be decreased when combined with Promazine. | Approved, Vet Approved |
| Promethazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Promethazine. | Approved |
| Proparacaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Proparacaine. | Approved, Vet Approved |
| Propofol | The serum concentration of Ropivacaine can be increased when it is combined with Propofol. | Approved, Investigational, Vet Approved |
| Propoxycaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Propoxycaine. | Approved |
| Propranolol | The risk or severity of adverse effects can be increased when Propranolol is combined with Ropivacaine. | Approved, Investigational |
| Protriptyline | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Protriptyline. | Approved |
| Quazepam | The serum concentration of Ropivacaine can be increased when it is combined with Quazepam. | Approved, Illicit |
| Quetiapine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Quetiapine. | Approved |
| Quinapril | The risk or severity of adverse effects can be increased when Quinapril is combined with Ropivacaine. | Approved, Investigational |
| Quinidine | The metabolism of Ropivacaine can be decreased when combined with Quinidine. | Approved |
| Quinine | The metabolism of Ropivacaine can be decreased when combined with Quinine. | Approved |
| Raclopride | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Raclopride. | Investigational |
| Ramelteon | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ramelteon. | Approved, Investigational |
| Ramipril | The risk or severity of adverse effects can be increased when Ramipril is combined with Ropivacaine. | Approved |
| Ranolazine | The metabolism of Ropivacaine can be decreased when combined with Ranolazine. | Approved, Investigational |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Ropivacaine. | Approved |
| Remifentanil | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Remifentanil. | Approved |
| Remoxipride | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Remoxipride. | Approved, Withdrawn |
| Reserpine | The risk or severity of adverse effects can be increased when Reserpine is combined with Ropivacaine. | Approved |
| Rifabutin | The metabolism of Ropivacaine can be increased when combined with Rifabutin. | Approved |
| Rifampicin | The metabolism of Ropivacaine can be increased when combined with Rifampicin. | Approved |
| Rifapentine | The metabolism of Ropivacaine can be increased when combined with Rifapentine. | Approved |
| Riociguat | The risk or severity of adverse effects can be increased when Riociguat is combined with Ropivacaine. | Approved |
| Risperidone | Ropivacaine may increase the hypotensive activities of Risperidone. | Approved, Investigational |
| Ritanserin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ritanserin. | Investigational |
| Ritonavir | The metabolism of Ropivacaine can be decreased when combined with Ritonavir. | Approved, Investigational |
| Rolapitant | The metabolism of Ropivacaine can be decreased when combined with Rolapitant. | Approved |
| Ropinirole | Ropivacaine may increase the sedative activities of Ropinirole. | Approved, Investigational |
| Rotigotine | Ropivacaine may increase the sedative activities of Rotigotine. | Approved |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Ropivacaine. | Approved |
| Sacubitril | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sacubitril. | Approved |
| Saquinavir | The metabolism of Ropivacaine can be decreased when combined with Saquinavir. | Approved, Investigational |
| Scopolamine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Scopolamine. | Approved |
| Secobarbital | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Secobarbital. | Approved, Vet Approved |
| Selegiline | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Selegiline. | Approved, Investigational, Vet Approved |
| Sepranolone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Uc1010. | Investigational |
| Sertindole | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sertindole. | Approved, Withdrawn |
| Sertraline | The metabolism of Ropivacaine can be decreased when combined with Sertraline. | Approved |
| Sevoflurane | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sevoflurane. | Approved, Vet Approved |
| Sildenafil | The metabolism of Ropivacaine can be decreased when combined with Sildenafil. | Approved, Investigational |
| Siltuximab | The serum concentration of Ropivacaine can be decreased when it is combined with Siltuximab. | Approved |
| Simeprevir | The serum concentration of Ropivacaine can be increased when it is combined with Simeprevir. | Approved |
| Sodium Nitrite | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sodium Nitrite. | Approved |
| Sodium oxybate | Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved |
| Sorafenib | The metabolism of Ropivacaine can be decreased when combined with Sorafenib. | Approved, Investigational |
| Sotalol | The risk or severity of adverse effects can be increased when Sotalol is combined with Ropivacaine. | Approved |
| Spironolactone | The risk or severity of adverse effects can be increased when Spironolactone is combined with Ropivacaine. | Approved |
| St. John's Wort | The serum concentration of Ropivacaine can be decreased when it is combined with St. John's Wort. | Nutraceutical |
| Stiripentol | The serum concentration of Ropivacaine can be increased when it is combined with Stiripentol. | Approved |
| Streptokinase | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Streptokinase. | Approved |
| Sufentanil | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sufentanil. | Approved, Investigational |
| Sulfisoxazole | The metabolism of Ropivacaine can be decreased when combined with Sulfisoxazole. | Approved, Vet Approved |
| Sulpiride | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sulpiride. | Approved |
| Suvorexant | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. | Approved |
| Tamsulosin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tamsulosin. | Approved, Investigational |
| Tandospirone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tandospirone. | Investigational |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. | Approved |
| Tasimelteon | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tasimelteon. | Approved |
| Technetium Tc-99m tilmanocept | Ropivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. | Approved |
| Telaprevir | The metabolism of Ropivacaine can be decreased when combined with Telaprevir. | Withdrawn |
| Telithromycin | The metabolism of Ropivacaine can be decreased when combined with Telithromycin. | Approved |
| Telmisartan | The risk or severity of adverse effects can be increased when Telmisartan is combined with Ropivacaine. | Approved, Investigational |
| Temazepam | The risk or severity of adverse effects can be increased when Temazepam is combined with Ropivacaine. | Approved |
| Tenofovir disoproxil | The metabolism of Ropivacaine can be decreased when combined with Tenofovir. | Approved, Investigational |
| Terazosin | The risk or severity of adverse effects can be increased when Terazosin is combined with Ropivacaine. | Approved |
| Terbinafine | The metabolism of Ropivacaine can be decreased when combined with Terbinafine. | Approved, Investigational, Vet Approved |
| Teriflunomide | The serum concentration of Ropivacaine can be decreased when it is combined with Teriflunomide. | Approved |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrabenazine. | Approved |
| Tetracaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetracaine. | Approved, Vet Approved |
| Tetrodotoxin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrodotoxin. | Investigational |
| Thalidomide | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. | Approved, Investigational, Withdrawn |
| Theophylline | The metabolism of Ropivacaine can be decreased when combined with Theophylline. | Approved |
| Thiamylal | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiamylal. | Approved, Vet Approved |
| Thiopental | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiopental. | Approved, Vet Approved |
| Thioridazine | The metabolism of Ropivacaine can be decreased when combined with Thioridazine. | Withdrawn |
| Thiotepa | The metabolism of Ropivacaine can be decreased when combined with Thiotepa. | Approved |
| Thiothixene | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiothixene. | Approved |
| Tiagabine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiagabine. | Approved |
| Tiapride | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiapride. | Approved, Investigational |
| Ticlopidine | The metabolism of Ropivacaine can be decreased when combined with Ticlopidine. | Approved |
| Timolol | The risk or severity of adverse effects can be increased when Timolol is combined with Ropivacaine. | Approved |
| Tipranavir | The metabolism of Ropivacaine can be decreased when combined with Tipranavir. | Approved, Investigational |
| Tizanidine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tizanidine. | Approved |
| Tocilizumab | The serum concentration of Ropivacaine can be decreased when it is combined with Tocilizumab. | Approved |
| Tolazoline | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolazoline. | Approved, Vet Approved |
| Tolcapone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolcapone. | Approved, Withdrawn |
| Topiramate | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Topiramate. | Approved |
| Torasemide | The risk or severity of adverse effects can be increased when Torasemide is combined with Ropivacaine. | Approved |
| Tramadol | The risk or severity of adverse effects can be increased when Tramadol is combined with Ropivacaine. | Approved, Investigational |
| Trandolapril | The risk or severity of adverse effects can be increased when Trandolapril is combined with Ropivacaine. | Approved |
| Trans-2-Phenylcyclopropylamine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trans-2-Phenylcyclopropylamine. | Experimental |
| Tranylcypromine | The metabolism of Ropivacaine can be decreased when combined with Tranylcypromine. | Approved |
| Trazodone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trazodone. | Approved, Investigational |
| Tretinoin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tretinoin. | Approved, Investigational, Nutraceutical |
| Triamterene | The risk or severity of adverse effects can be increased when Triamterene is combined with Ropivacaine. | Approved |
| Triazolam | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Triazolam. | Approved |
| Trifluoperazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trifluoperazine. | Approved |
| Triflupromazine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Triflupromazine. | Approved, Vet Approved |
| Trimipramine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trimipramine. | Approved |
| Triprolidine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Triprolidine. | Approved |
| Valproic Acid | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Valproic Acid. | Approved, Investigational |
| Valsartan | The risk or severity of adverse effects can be increased when Valsartan is combined with Ropivacaine. | Approved, Investigational |
| Vemurafenib | The serum concentration of Ropivacaine can be increased when it is combined with Vemurafenib. | Approved |
| Venlafaxine | The metabolism of Ropivacaine can be decreased when combined with Venlafaxine. | Approved |
| Verapamil | The metabolism of Ropivacaine can be decreased when combined with Verapamil. | Approved |
| Vigabatrin | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Vigabatrin. | Approved |
| Voriconazole | The metabolism of Ropivacaine can be decreased when combined with Voriconazole. | Approved, Investigational |
| Vortioxetine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Vortioxetine. | Approved |
| Zaleplon | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zaleplon. | Approved, Illicit, Investigational |
| Ziconotide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ziconotide. | Approved |
| Zimelidine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zimelidine. | Withdrawn |
| Ziprasidone | The metabolism of Ropivacaine can be decreased when combined with Ziprasidone. | Approved |
| Zolpidem | Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. | Approved |
| Zonisamide | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zonisamide. | Approved, Investigational |
| Zopiclone | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zopiclone. | Approved |
| Zotepine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zotepine. | Approved |
| Zuclopenthixol | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zuclopenthixol. | Approved, Investigational |
